Abstract
Despite the impressive results of one-year survival rates, organ transplantation still faces major problems. Current anti-rejection drugs reduce systemic immunity nonselectively and increase the risk of infection and cancer on the long term. Theoretically, selective inhibition of alloimmune response can be achieved at the organ level by intragraft transfer of genes with immunomodulatory properties. In the last decade, gene therapy emerged as a new strategy in renal, heart and liver transplantation, showing promising results in experimental animals, almost in controlling acute rejection. The success of gene therapy in the transplant medicine is strongly dependent on the efficiency of the delivery system that allows local transfer and expression of the therapeutic gene in the target organ or tissue. The main findings concerning the suitability of gene therapy in preventing graft rejection will be discussed here.
| Original language | English |
|---|---|
| Title of host publication | Contributions to Nephrology |
| Pages | 143-150 |
| Number of pages | 8 |
| Volume | 146 |
| Publication status | Published - 2005 |
Publication series
| Name | Contributions to Nephrology |
|---|---|
| Volume | 146 |
| ISSN (Print) | 03025144 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
The goal of intragraft gene therapy. / Tomasoni, Susanna; Benigni, Ariela.
Contributions to Nephrology. Vol. 146 2005. p. 143-150 (Contributions to Nephrology; Vol. 146).Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - The goal of intragraft gene therapy
AU - Tomasoni, Susanna
AU - Benigni, Ariela
PY - 2005
Y1 - 2005
N2 - Despite the impressive results of one-year survival rates, organ transplantation still faces major problems. Current anti-rejection drugs reduce systemic immunity nonselectively and increase the risk of infection and cancer on the long term. Theoretically, selective inhibition of alloimmune response can be achieved at the organ level by intragraft transfer of genes with immunomodulatory properties. In the last decade, gene therapy emerged as a new strategy in renal, heart and liver transplantation, showing promising results in experimental animals, almost in controlling acute rejection. The success of gene therapy in the transplant medicine is strongly dependent on the efficiency of the delivery system that allows local transfer and expression of the therapeutic gene in the target organ or tissue. The main findings concerning the suitability of gene therapy in preventing graft rejection will be discussed here.
AB - Despite the impressive results of one-year survival rates, organ transplantation still faces major problems. Current anti-rejection drugs reduce systemic immunity nonselectively and increase the risk of infection and cancer on the long term. Theoretically, selective inhibition of alloimmune response can be achieved at the organ level by intragraft transfer of genes with immunomodulatory properties. In the last decade, gene therapy emerged as a new strategy in renal, heart and liver transplantation, showing promising results in experimental animals, almost in controlling acute rejection. The success of gene therapy in the transplant medicine is strongly dependent on the efficiency of the delivery system that allows local transfer and expression of the therapeutic gene in the target organ or tissue. The main findings concerning the suitability of gene therapy in preventing graft rejection will be discussed here.
UR - http://www.scopus.com/inward/record.url?scp=16544376027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16544376027&partnerID=8YFLogxK
M3 - Chapter
C2 - 15567928
AN - SCOPUS:16544376027
SN - 3805578563
SN - 9783805578561
VL - 146
T3 - Contributions to Nephrology
SP - 143
EP - 150
BT - Contributions to Nephrology
ER -